ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0592

An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Abstract Number: 0593

Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
Abstract Number: 0594

Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
Abstract Number: 0595

Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Abstract Number: 0596

Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Abstract Number: 0597

Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Abstract Number: 0598

Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
Abstract Number: 0599

Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Abstract Number: 0600

Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Abstract Number: 0601

Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Abstract Number: 0602

Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Abstract Number: 0603

Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Abstract Number: 0604

Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
Abstract Number: 0605

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Abstract Number: 0606

Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].